1671-87-0

Basic information

• Product Name: 3,6-DI-2-PYRIDYL-1,2,4,5-TETRAZINE
• Synonyms: Bptz 3,6-Bis(2-pyridinyl)-1,2,4,5-tetrazine 3,6-Di-2-pyridyl-s-tetrazine;3,6-Bis(2-pyridyl)-1,2,4,5-tetrazine;3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine;3,6-Di-2-pyridyl-1,2,4,5-tetrazine 96%;3,6-BIS(2-PYRIDINYL)-1,2,4,5-TETRAZINE;3,6-DI-2-PYRIDINYL-1,2,4,5-TETRAZINE;3,6-DI-2-PYRIDYL-1,2,4,5-TETRAZINE;3,6-DI-2-PYRIDYL-S-TETRAZINE
• CAS NO: 1671-87-0
• Molecular Formula: C₁₂H₈N₆
• Molecular Weight: 236.23
• Product Categories: Heterocyclic Compounds;Heterocyclic Building Blocks;N-Containing;Others
• Mol File: 1671-87-0.mol
• Article Data: 11

Chemical Properties

• Melting Point: 225 °C (dec.)(lit.)
• Boiling Point: 509.1°Cat760mmHg
• Flash Point: 245.7°C
• Appearance: /
• Density: 1.317g/cm³
• Vapor Pressure: 5.59E-10mmHg at 25°C
• Refractive Index: 1.632
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -1.77±0.11(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 3,6-DI-2-PYRIDYL-1,2,4,5-TETRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-DI-2-PYRIDYL-1,2,4,5-TETRAZINE(1671-87-0)
• EPA Substance Registry System: 3,6-DI-2-PYRIDYL-1,2,4,5-TETRAZINE(1671-87-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 1671-87-0(Hazardous Substances Data)

Usage

Uses

3,6-Di-2-pyridyl-1,2,4,5-tetrazine may be used in the preparation of mononuclear, cyclic tetranuclear, and 1-D helical-chain Cu(II) complexes, via metal-assisted hydrolysis. It also may be used in the synthesis of novel cyclic tetranuclear ZnII complex and synthesis of substituted 3,6-di(2-pyridyl)pyridazines, via inverse electron demand Diels Alder reaction with alkenes or alkynes.

General Description

3,6-Di-2-pyridyl-1,2,4,5-tetrazine undergoes solid-state reaction with fullerene C60 by high-speed vibration milling technique. It acts as electron-deficient diene in the inverse electron demand Diels Alder reaction.

InChI:InChI=1/C12H8N6/c1-3-7-13-9(5-1)11-15-17-12(18-16-11)10-6-2-4-8-14-10/h1-8H

Upstream product

• 100-70-9 2-Cyanopyridine 
• 75-05-8 acetonitrile 
• 1671-86-9 3,6-bis(2-pyridyl)-1,2-dihydro-1,2,4,5-tetrazine 
• 1671-86-9 3,6-di(pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazine 
• 19081-87-9 N,N'-bis(picolinamide)azine 
• 74222-83-6 benzamidine hydrochloride dihydrate 
• 65520-11-8 2-cyano-pyridine hydrochloride 

Downstream Products

• 126976-84-9 (3,6-bis(2-pyridyl)-1,2,4,5-tetrazine)(Au(PPh₃))2⁽¹⁺⁾ radical 
• 1031820-30-0 C₂₀H₁₃BrN₄ 
• 1031820-25-3 4-(4-nitrophenyl)-3,6-di(2-pyridyl)pyridazine 
• 1031820-29-7 C₂₆H₁₈N₄ 
• 1031820-51-5 1,3,5-tris{3,6-bis(2-pyridyl)pyridazin-4-yl}benzene 
• 1031820-41-3 C₂₀H₁₃BrN₄ 

Relevant articles and documents

A novel route to fully substituted 1H-pyrazoles

A novel one-step synthesis route to fully substituted pyrazol-4-ols is reported. This simple yet nonobvious method for the construction of pyrazol-4-ols by the condensation-fragmentation-cyclization-extrusion reactions of thietanones with 1,2,4,5-tetrazin

Functionalized 2,5-dipyridinylpyrroles by electrochemical reduction of 3,6-dipyridinylpyridazine precursors

The ring contraction of pyridinylpyridazine derivatives into the corresponding pyrroles by electrochemical reduction was studied, and the influence of the substituents of the pyridazine precursors on the process is discussed. Cyclic voltammetry studies underlines the electron-withdrawing or -donating effect of the substituent on the pyridazine ring, which determines the reaction pathway of their preparative electrolysis. The ring-contraction process, with extrusion of nitrogen, proceeds by two subsequent two-electron, two-proton processes via a 1,2-dihydropyridazine intermediate. The latter can either rearrange into an isolable 1,4-dihydropyridazine or undergo formation of pyrroles by disproportionation or by a second electrochemical reduction involving two-electrons and two protons. X-ray structure, fluorescence spectra, and conformational analysis of pyridinylpyrrole sequences supported this study. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

BIO-ORTHOGONAL DRUG ACTIVATION

The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.

3,6-Substituted-1,2,4,5-tetrazines: Tuning reaction rates for staged labeling applications

Cycloaddition reactions involving tetrazines have proven to be powerful bioorthogonal tools for various applications. Conceivably, sequential and selective labeling using tetrazine-based reactions can be achieved by tuning the reaction rate. By varying th